3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
6
Polycystic Ovary Syndrome
5
Ovarian Hyperstimulation Syndrome
3
Infertility
3
Breast Neoplasms
2
The Neoadjuvant Therapy
1
Sarcoma, Ewing
1
Sarcoma
1
Osteosarcoma
1
Neoplasms
1
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
1
Lymphoma
1
Helping Behavior
1
Interventions
Doxorubicin
19
Radiotherapy
10
Ifosfamide
10
apatinib
9
anlotinib
8
Cyclophosphamide
8
camrelizumab
7
Vincristine
5
Dactinomycin
5
toripalimab
3
Trabectedin
3
Radiation Dose Hypofractionation
3
Etoposide
3
Docetaxel
3
ribociclib
2
brostallicin
2
Topotecan
2
Thalidomide
2
Temozolomide
2
Sorafenib
2
Oncolytic Virotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Gene Expression Profiling
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Sarcoma
×
Triptorelin Pamoate
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled